Table 2.

Summary of Phase II and III Trials with Main Results from Initiation of Treatment to Week 12 or 16

Study	Patients, N	Dosage	PASI75 (% Patients)	PGA Score of 0 or 1 with ≥2 Reduction from Baseline	PASI90 (% patients)	DLQI of 0 og 1 (% Patients)
Papp et al25 Phase IIb	355 split in a 1:2:2:2:1 ratio	tildrakizumab 5 mg (n=42) tildrakizumab 25 mg (n=92) tildrakizumab 100 mg (n=89) tildrakizumab 200 mg (n=86) placebo (n=46)	tildrakizumab 5 mg: 33% tildrakizumab 25 mg: 64% tildrakizumab 100 mg: 66% tildrakizumab 200 mg: 74% placebo: 4%	tildrakizumab 5 mg: 33% tildrakizumab 25 mg: 58% tildrakizumab 100 mg: 62% tildrakizumab 200 mg: 74% placebo: 2%	tildrakizumab 5 mg: 12% tildrakizumab 25 mg: 25% tildrakizumab 100 mg: 39% tildrakizumab 200 mg: 52% placebo: 2%	tildrakizumab 5 mg: 32% tildrakizumab 25 mg: 57% tildrakizumab 100 mg: 52% tildrakizumab 200 mg: 57% placebo: 0%
Reich et al26 Phase III reSURFACE 1	772 split in a 2:2:1 ratio	tildrakizumab 100 mg (n=309) tildrakizumab 200 mg (n=308) placebo (n=155)	tildrakizumab 100 mg; 64% tildrakizumab 200 mg: 62% placebo: 6%	tildrakizumab 100 mg; 58% tildrakizumab 200 mg: 59% placebo: 7%	tildrakizumab 100 mg; 35% tildrakizumab 200 mg: 35% placebo: 3%	tildrakizumab 100 mg; 42% tildrakizumab 200 mg: 44% placebo: 5%
Reich et al26 Phase III reSURFACE 2	1090 split in a 2:2:1:2 ratio	tildrakizumab 100 mg (n=307) tildrakizumab 200 mg (n=314) placebo (n=156) etanercept 50 mg (n=313)	tildrakizumab 100 mg: 61% tildrakizumab 200 mg: 66% placebo: 6% etanercept 50 mg: 48%	tildrakizumab 100 mg: 55% tildrakizumab 200 mg: 59% placebo: 4% etanercept 50 mg: 48%	tildrakizumab 100 mg: 39% tildrakizumab 200 mg: 37% placebo: 1% etanercept 50 mg: 21%	tildrakizumab 100 mg: 40% tildrakizumab 200 mg: 47% placebo: 8% etanercept 50 mg: 36%

Abbreviations: PASI75, 75% improvement in Psoriasis Area and Severity Index; PGA, Physician´s Global Assessment; DLQI, Dermatology Life Quality Index.